跳至主要内容
临床试验/JPRN-UMIN000035668
JPRN-UMIN000035668已完成未知

Cohort study of patients with initially unresectable pancreatic cancer in whom conversion surgery is planned after FOLFIRINOX or gemcitabine plus nab-paclitaxel therapy - PC-CURE-1

Federation of Asian Clinical Oncology (FACO)0 个研究点目标入组 360 人开始时间: 2019年1月26日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
360

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
ot applicable 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1. Borderline resectable disease by NCCN Guidelines Ver 2.2018 is excluded in this study. Solid tumor contact with the CA >180 degrees is classified to unrsectable. 2. Recurrent disease 3. Response to chemotherapy according to RECIST ver 1.1 was PD 4. Heavy ion radiotherapy or proton beam therapy performed before laparotomy 5. Diagnosed as unresectable disease by examination laparoscopic when was intented to conversion surgery 6. Resection of metastatic lesions at conversion surgery. However, patients can be registered unless they are pathologically demonstrated to have cancer after dissection of the 16th lymph node or hepatectomy. 7. Peritoneal lavage cytology positive

研究者

发起方
Federation of Asian Clinical Oncology (FACO)

相似试验

Cohort study of patients with initially unresectable... | 临床试验